Evidence map›Paper›PMID 38704374›Full record

ArticleCell death & disease2024

Study of the potential role of CASPASE-10 mutations in the development of autoimmune lymphoproliferative syndrome.

Filippo Consonni, Solange Moreno, Blanca Vinuales Colell, Marie-Claude Stolzenberg, Alicia Fernandes, Mélanie Parisot, Cécile Masson, Nathalie Neveux, Jérémie Rosain, Sarah Bamberger and 6 more

Abstract read
In one paragraph

Article in Cell death & disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Filippo ConsonniDepartment of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, Florence, Italy.ORCID 0000-0002-6879-8982
Solange Moreno *University of Paris Cité, Paris, France.
Blanca Vinuales Colell *University of Paris Cité, Paris, France.
Marie-Claude StolzenbergUniversity of Paris Cité, Paris, France.
Alicia FernandesPlateforme Vecteurs Viraux et Transfert de Gènes, SFR Necker, INSERM US 24/CNRS UAR 3633, Faculté de santé Necker, Paris, France.ORCID 0009-0008-8846-0031
Mélanie ParisotUniversity of Paris Cité, Paris, France.
Cécile MassonUniversity of Paris Cité, Paris, France.
Nathalie NeveuxLaboratory of Biological Nutrition, EA 4466, Faculty of Pharmacy, Paris University, Paris, France.
Jérémie RosainUniversity of Paris Cité, Paris, France.
Sarah BambergerPediatrics Gastroenterology and Nutrition, Robert-Debré Hospital, Paris, France.
Marie-Gabrielle ViguePediatrics, Infectiology, Rhumatology, Hôpital Arnaud-de-Villeneuve, CHRU de Montpellier, Montpellier, France.
Marion MalphettesUniversity of Paris Cité, Paris, France.
Pierre QuartierUniversity of Paris Cité, Paris, France.
Capucine PicardUniversity of Paris Cité, Paris, France.
Frédéric Rieux-LaucatUniversity of Paris Cité, Paris, France.ORCID 0000-0001-7858-7866
Aude MagerusUniversity of Paris Cité, Paris, France. aude.magerus@inserm.fr.ORCID 0000-0001-7365-699X

Funding

Agence Nationale de la Recherche (French National Research Agency) ANR-10-IAHU-01Agence Nationale de la Recherche (French National Research Agency) ANR-14-CE14-0026-01Agence Nationale de la Recherche (French National Research Agency) ANR-18-CE17-0001Agence Nationale de la Recherche (French National Research Agency) ANR-18-RHUS-0010Agence Nationale de la Recherche (French National Research Agency) ANR-22-CE15-0047-02Fondation pour la Recherche Médicale (Foundation for Medical Research in France) EQU202103012670
6 · The paper itself

Abstract

Autoimmune lymphoproliferative syndrome (ALPS) is a primary disorder of lymphocyte homeostasis, leading to chronic lymphoproliferation, autoimmune cytopenia, and increased risk of lymphoma. The genetic landscape of ALPS includes mutations in FAS, FASLG, and FADD, all associated with apoptosis deficiency, while the role of CASP10 defect in the disease remains debated. In this study, we aimed to assess the impact of CASP10 variants on ALPS pathogenesis. We benefit from thousands of genetic analysis datasets performed in our Institute's genetic platform to identify individuals carrying CASP10 variants previously suspected to be involved in ALPS outcome: p.C401LfsX15, p.V410I and p.Y446C, both at heterozygous and homozygous state. Clinical and laboratory features of the six included subjects were variable but not consistent with ALPS. Two individuals were healthy. Comprehensive analyses of CASP10 protein expression and FAS-mediated apoptosis were conducted and compared to healthy controls and ALPS patients with FAS mutations. Missense CASP10 variants (p.V410I and p.Y446C), which are common in the general population, did not disrupt CASP10 expression, nor FAS-mediated apoptosis. In contrast, homozygous p.C401LfsX15 CASP10 variant lead to a complete abolished CASP10 expression but had no impact on FAS-mediated apoptosis function. At heterozygous state, this p.C401LfsX15 variant lead to a reduced CASP10 protein levels but remained associated with a normal FAS-mediated apoptosis function. These findings demonstrate that CASPASE 10 is dispensable for FAS-mediated apoptosis. In consequences, CASP10 defect unlikely contribute to ALPS pathogenesis, since they did not result in an impairment of FAS-mediated apoptosis nor in clinical features of ALPS in human. Moreover, the absence of FAS expression up-regulation in subjects with CASP10 variants rule out any compensatory mechanisms possibly involved in the normal apoptosis function observed. In conclusion, this study challenges the notion that CASP10 variants contribute to the development of ALPS.

Indexed as

ApoptosisAutoimmune Lymphoproliferative SyndromeCaspase 10fas ReceptorMutationAdolescentAdultChildFemaleHumansMaleMiddle AgedCASP10 protein, humanCaspase 10FAS protein, humanfas Receptor

Identifiers

PMID38704374
PMCPMC11069523

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.